Concert Pharmaceuticals (CNCE) Upgraded by TheStreet to B-

TheStreet upgraded shares of Concert Pharmaceuticals (NASDAQ:CNCE) from a c+ rating to a b- rating in a research report sent to investors on Monday.

Other analysts have also issued research reports about the company. Zacks Investment Research lowered Concert Pharmaceuticals from a buy rating to a hold rating in a report on Friday, September 15th. HC Wainwright restated a buy rating and set a $21.00 target price on shares of Concert Pharmaceuticals in a report on Friday, October 20th. Stifel Nicolaus restated a buy rating and set a $30.00 target price on shares of Concert Pharmaceuticals in a report on Sunday, October 22nd. Mizuho began coverage on Concert Pharmaceuticals in a report on Thursday, October 26th. They set a buy rating and a $23.00 target price for the company. Finally, UBS Group set a $34.00 target price on Concert Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, December 19th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $24.83.

Concert Pharmaceuticals (NASDAQ CNCE) traded down $0.35 during trading on Monday, reaching $27.68. The company’s stock had a trading volume of 265,448 shares, compared to its average volume of 314,969. The stock has a market capitalization of $638.32, a price-to-earnings ratio of 7.38 and a beta of 1.67. Concert Pharmaceuticals has a one year low of $8.61 and a one year high of $30.71.

In other news, Director Ronald W. Barrett sold 14,156 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $24.70, for a total transaction of $349,653.20. Following the completion of the sale, the director now owns 3,539 shares in the company, valued at approximately $87,413.30. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Value Fund L. P. Biotechnology acquired 331,916 shares of the firm’s stock in a transaction dated Thursday, October 19th. The shares were acquired at an average price of $15.84 per share, with a total value of $5,257,549.44. The disclosure for this purchase can be found here. Corporate insiders own 10.10% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of CNCE. SG Americas Securities LLC purchased a new stake in shares of Concert Pharmaceuticals during the 3rd quarter valued at $153,000. Alliancebernstein L.P. purchased a new stake in shares of Concert Pharmaceuticals during the 2nd quarter valued at $174,000. State of Wisconsin Investment Board purchased a new stake in shares of Concert Pharmaceuticals during the 2nd quarter valued at $181,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Concert Pharmaceuticals by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock valued at $210,000 after purchasing an additional 287 shares during the last quarter. Finally, Princeton Capital Management Inc. purchased a new stake in shares of Concert Pharmaceuticals during the 3rd quarter valued at $215,000. Hedge funds and other institutional investors own 65.29% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.com-unik.info/2018/01/11/concert-pharmaceuticals-cnce-upgraded-by-thestreet-to-b.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit